Resveratrol from Red Grapes – Pedestrian Polyphenol or Useful Anticancer Agent?

Abstract

Resveratrol is a phytoalexin with cancer chemopreventive properties in preclinical models of carcinogenesis. The mechanisms via which resveratrol is thought to exert chemopreventive efficacy are inhibition of cyclooxygenase enzymes, inhibition of angiogenesis, modulation of drug metabolising enzymes, antioxidation and alterations of cell cycle components and apoptotic machinery. Pharmacokinetic evidence in rodents and humans suggests that the bioavailability of resveratrol is very low and that resveratrol conjugates are the major circulating agent-derived species. The recent realisation that resveratrol can mimic caloric restriction in several species has generated a lot of interest. Attempts to design analogues with the aim of optimising resveratrol pharmacology have furnished stilbenes with different aryl subtituents, e. g., methoxy instead of hydroxy. Some of these derivatives possess more potent pharmacological properties than the lead compound. More work is required to elucidate the role of metabolites in the pharmacological activity of resveratrol.

Key words

Resveratrol - cancer chemoprevention - caloric restriction - analogues

References

• 1 Siemann E H, Creasy L L. Concentration of the phytoalexin resveratrol in wine.  Am J Eno Vitic. 1992;  43 49-52
• 2 Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W. et al . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 1997;  275 218-20
• 3 Gescher A J, Steward W P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum.  Cancer Epidemiol Biomarkers Prev. 2003;  12 953-7
• 4 Baur J A, Sinclair D A. Therapeutic potential of resveratrol: the in vivo evidence.  Nat Rev Drug Discov. 2006;  5 493-506
• 5 Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol.  Mol Nutr Food Res. 2005;  49 472-81
• 6 Aggarwal B B, Shishodia S. Resveratrol in health and disease. Boca Raton, FL; CRC Press, Taylor and Francis Group 2006
• 7 Oshima M, Dinchuk J E, Kargman S L, Oshima H, Hancock B, Kwong E. et al . Suppression of intestinal polyposis in Apcδ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).  Cell. 1996;  87 803-9
• 8 Li Z G, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y. et al . Suppression of N-nitroso-methylbenzylamine (NMBA)-induced esophagael tumourigenesis in F344 rats by resveratrol.  Carcinogenesis. 2002;  23 1531-6
• 9 Aziz M, Afaq F, Ahmad N. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin.  Photochem Photobiol. 2004;  81 25-31
• 10 Subbaramaiah K, Chung W J, Michaluart P, Telang N, Tanabe T, Inoue H. et al . Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells.  J Biol Chem. 1998;  273 21 875-82
• 11 Martin A R, Villegas I, La Casa C, de la Lastra C A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats.  Biochem Pharmacol. 2004;  67 1399-1410
• 12 Kimura Y, Okuda H. Resveratrol isolated from Polygonuum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularisation in Lewis lung carcinoma-bearing mice.  J Nutr. 2001;  131 1844-9
• 13 Tseng S H, Lin S M, Chen J C, Su Y H, Huang H Y, Chen C K. et al . Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats.  Clin Cancer Res. 2004;  10 2190-2
• 14 Yu C, Shin Y G, Kosmeder J W, Pezzuto J M, van Breemen R B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.  Rapid Commun Mass Spectrom. 2003;  17 307-13
• 15 Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.  Toxicol Lett. 2001;  125 83-91
• 16 Chang T K, Lee W B, Ko H H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1.  Can J Physiol Pharmacol. 2000;  78 874-81
• 17 Chan W K, Delucchi A B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.  Life Sci. 2000;  67 3103-12
• 18 Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury.  Eur J Pharmacol. 2004;  489 39-48
• 19 Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol – a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis.  Carcinogenesis. 2005;  27 1038-46
• 20 Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats.  Life Sci. 2003;  73 1393-400
• 21 Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats.  Mol Nutr Food Res. 2005;  49 482-94
• 22 Clement M V, Hirpara J L, Chawdhury S H, Pervaiz S. The chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells.  Blood. 1998;  92 996-1002
• 23 Yu L, Sun Z J, Wu S K, Pan C E. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.  World J Gastroenterol. 2003;  9 2341-3
• 24 Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumourigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis.  Nutr Cancer. 2001;  39 102-7
• 25 Reagan-Shaw S, Afaq F, Aziz M H, Ahmad N. Modulation of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin.  Oncogene. 2004;  23 5151-60
• 26 Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.  Cancer Lett. 2006;  231 113-22
• 27 Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio G. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.  Int J Cancer. 2005;  115 36-45
• 28 Zhou H B, Chen J J, Wang W X, Cai J T, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice.  World J Gastroenterol. 2005;  11 280-4
• 29 Fulda S, Debatin K M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.  Cancer Res. 2004;  64 337-46
• 30 Baur J A, Pearson K J, Price N L, Jamieson H A, Lerin C, Kalra A. et al . Resveratrol improves health and survival of mice on a high-calorie diet.  Nature. 2006;  444 337-42
• 31 Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F. et al . Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha.  Cell. 2006;  127 1109-22
• 32 Ahmad K A, Clement M V, Hanif I M, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu non-permissive for death execution.  Cancer Res. 2004;  64 1452-9
• 33 Marier J F, Vachon P, Gritsas A, Zhang J, Moreau J P, Ducharme M P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.  J Pharmacol Exp Ther. 2002;  320 369-73
• 34 Asensi M, Medina I, Ortega A, Carretero J, Bano M C, Obrador E. et al . Inhibition of cancer growth by resveratrol is related to its low bioavailability.  Free Radic Biol Med. 2002;  33 387-98
• 35 Walle T, Hsieh F, DeLegge M H, Oatis J E, Walle U K. High absorption but very low bioavailability of oral resveratrol in humans.  Drug Metab Disp. 2004;  32 1377-82
• 36 Boocock D J, Faust G ES, Patel K R, Schinas A M, Brown V A, Ducharme M P. et al . Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.  Cancer Epidemiol Biomarkers Prev. 2007;  16 1246-52
• 37 Meng X F, Maliakal P, Lu H, Lee M J, Yang C S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice.  J Agric Food Chem. 2004;  52 935-42
• 38 Zern T L, Wood R J, Greene C, West K L, Liu Y Z, Aggarwal D. et al . Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress.  J Nutr. 2005;  135 1911-7
• 39 Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi P P. et al . Bioavailability of trans-resveratrol from red wine in humans.  Mol Nutr Food Res. 2005;  49 495-504
• 40 Goldberg D A, Yan J, Soleas G J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects.  Clin Biochem. 2003;  36 79-87
• 41 Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos R M, Estruch R, Vazquez-Agell M, Serrano-Martinez M. et al . Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption.  Clin Chem. 2006;  52 1373-80
• 42 Lekakis J, Rallidis L S, Andreadou I, Vamvakou G, Kazantzoglou G, Magiatis P. et al . Polyphenolic compunds from red grapes acutely improve endothelial function in patients with coronary heart disease.  Eur J Cardiovasc Prev Rehabil. 2005;  12 596-600
• 43 Pervaiz S. Resveratrol: from grapevines to mammalian biology.  FASEB J. 2003;  17 1975-85
• 44 Russo G L. Ins and outs of dietary phytochemicals in cancer chemoprevention.  Biochem Pharmacol. 2007;  74 533-44
• 45 Howells L M, Moiseeva E P, Neal C P, Foreman B E, Kandreadi C K, Sun Y Y. et al . Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals.  Acta Pharmacol Sin. 2007;  28 1274-304
• 46 Crowell J A, Korytko P J, Morrissey R L, Booth T D, Levine B S. Resveratrol-associated renal toxicity.  Toxicol Sci. 2004;  82 614-9
• 47 Pettit G R, Grealish M P, Jung M K, Hamel E, Pettit R K, Chapuis J C. et al . Antineoplastic agents. 465. Structural modification of resveratrol: sodium resveratrin phosphate.  J Med Chem. 2002;  45 2534-42
• 48 Kim S, Ko H, Park J E, Jung S, Lee S K, Chun Y J. Design, synthesis and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.  J Med Chem. 2002;  45 160-4
• 49 Thakkar K, Geahlen R L, Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol.  J Med Chem. 1993;  36 2950-5
• 50 Cushman M, Nagarathnam D, Gopal D, He H M, Lin C M, Hamel E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.  J Med Chem. 1992;  35 2293-306
• 51 Heynekamp J J, Weber W M, Hunsaker L A, Gonzales A M, Orlando R A, Deck L M. et al . Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB.  J Med Chem. 2006;  49 7182-9
• 52 Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C. et al . Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.  J Med Chem. 2003;  46 3546-54
• 53 Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T. et al . Antioxidant prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship.  Biochem Pharmacol. 2005;  69 903-12
• 54 Suh N, Paul S, Hao X P, Simi B, Xiao H, Rimando A M. et al . Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats.  Clin Cancer Res. 2007;  13 350-5